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Using a new method, rabbit IgG and a monoclonal antibody have been conjugated with the chelating agent 
DTPA. This was accomplished with reaction conditions that should entail lower antibody damage than 
existing methods. Gel filtration of the “‘In-labelled antibody conjugate indicated minimal damage to the 
antibody and radioimmunoassay showed no significant change in its immunological activity. 
Isotope labelling Indium 
1. INTRODUCTION 2. MATERIALS AND METHODS 
Radioiodinated antibodies have been employed 
for some time in the detection of tumours [ 1,2] but 
recently the use of “‘In as a label has been in- 
vestigated 13-51. Its advantages are that it has gam- 
ma energies favourable for imaging, a convenient 
half-life and it does not emit high energy beta 
radiation [6,7]. Labelling with “‘In entails the at- 
tachment of a chelating agent to the antibody; the 
conjugate is then able to bind “‘Ir?+. Some 
methods involving multi-step chemical syntheses 
[8,9] would present problems for many clinical 
laboratories. Simpler procedures employing the 
chelating agent DTPA have been devised but these 
generally use high molar ratios of chelating reagent 
or involve other experimental conditions that 
could damage or aggregate fragile antibodies 
[3,5,10,11]. Here we report a new and efficient 
method for attaching DTPA which we believe 
avoids these difficulties. 
Preliminary experiments used rabbit IgG 
(Miles), those involving a specific antibody used a 
mouse monoclonal a.HCG [ 121. All water was 
distilled using glass apparatus and the DMSO was 
carefully dried. Reagents used were of the highest 
grade available. 
2.1. Preparation of the DTPA-IgG conjugate 
DTPA (197 mg, 0.5 mmol) was dissolved in 
DMSO (9.5 ml) at 90°C and the solution allowed 
to cool. To the stirring solution was added, drop- 
wise, a solution of N-hydroxysuccinimide (57.6 
mg, 0.5 mmol) in DMSO (2.0 ml) and then, drop- 
wise, a solution of dicyclohexylcarbodiimide (92.9 
mg, 0.45 mmol) in DMSO (2.5 ml). After stirring 
overnight the mixture was filtered. The volume of 
filtrate required to give the desired molar ratio of 
DTPA was then slowly added to a solution of the 
IgG in 0.1 M sodium phosphate, 0.1 M NaCl buf- 
fer (pH 8.0), IgG concentration 2.6-3.4 mg/ml. 
After stirring for 2 h at room temperature the solu- 
tion was applied to a Bio-Gel P30 column (27 x 1.5 
cm) and eluted using 0.9% NaCl, 0.02% NaN3. 
The IgG fraction was dialysed for 24 h at 4°C 
against 3 changes of 800 ml of 0.9% NaCl, 0.02% 
NaNJ and then for 20 h at 4°C against 3 changes 
Abbreviations: DTPA, diethylenetriaminepentaacetic 
acid; a.HCG, antibody to human chorionic gonadotro- 
phin; DMSO, dimethyl sulphoxide 
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of 800 ml of 0.1 M sodium citrate buffer (pH 5.0). Dr N.J. Haskins. A VG Analytical ZAB-HF mass 
The solution was then aliquoted and stored at spectrometer equipped with a FAB source was 
- 70°C. used. 
A soiution (0.2 ml) of r”InCI~ in 0.04 M HCI 
(607 MBq/ml) (Amersham International plc, pro- 
duct code INS IP) was added dropwise to 0.3 ml of 
the stirring conjugate solution. The pH was kept at 
5.0 by the addition of 0.05 M NaOH. After stirring 
for 40 min the solution was applied to a Bio-Gel 
P30 column (27 x 1.5 cm) and eluted with 0.1 M 
sodium citrate buffer (pH 5.0), the radioactivity of 
the fractions being monitored. The IgG fraction 
was rechromatographed on a Bio-Gel P30 column 
(25 x 1.5 cm) eiuting with 0.9% NaCI. The product 
was then fihered (Microff ow 25, pore size 0.2 ym). 
3. RESULTS AND DISCUSSION 
The intention of the study was to label a.HCG 
with “‘In via a DTPA-a.HCG conjugate formed 
by reaction of the antibody with the N- 
succinimidyl ester of DTPA. The preparation of 
the ester was based on previous methods for mak- 
ing similar derivatives [13,14]. Although the ester 
was not isolated, a mass spectrometric investiga- 
tion of its DMSO solution showed a signal at m/z 
489 corresponding to the ester anion. The max- 
imum specific activities obtained from IabeI~ng a 
series of DTPA-IgG conjugates are given in table 
1. 
2.2.1, Radioimmunoassay and gel filtration 
The ‘“‘In-DTPA-a.HCG conjugate used for 
these studies was prepared using a 12 molar excess 
of DTPA over the antibody. It had a specific ac- 
tivity of 170 MBq/mg. A radioimmunoassay [12] 
was conducted both on the conjugate and on a 
sample of the a.HCG used in its preparation. For 
the gel filtration (fig.2) samples of the conjugate 
and of the a.HCG were applied to a Sephacryl 
S-300 column (86 x 1.5 cm) and eluted with a 0.05 
M sodium phosphate, 0.15 M NaCI, 0.02% NaNs 
buffer (pH 7.0) at a flow-rate of 9.6 ml/h at 4°C. 
It could be argued that dicyclohexylcar- 
bodiimide is capable of linking DTPA to IgG 
either directly or via the formation of an anhydride 
species. Thus the reaction was simulated in the 
absence of N-hydroxysuccinimide in order to 
demonstrate the necessity of using this reagent. 
The resulting product had a lower ability to bind 
“IIn (table 1). The use of the carbodiimide in sub- 
stoichiomet~c quantities in the ester prep~ation 
was not only to discourage the possibility of the 
above reactions but aIso to avoid unreacted 
reagent causing antibody dimer formation. 
2.3. Mass spectrometry 
This was conducted at M-Scan Ltd. (Ascot) by 
The radioimmunoassay of the “‘In-DTPA- 
a.HCG conjugate (fig.1) showed that the coupling 
and labelling procedure had not significantly 
altered the immunological action of the antibody. 
Gel filtration (fig.2) indicated little protein damage 50- 
30- 2 . \ 
d 
_\\ 
0 
/ 
Of I 
IO.0 I.0 0.1 0.01 
a.HCG concn pg/rnl 
Fig. 1. Radioimmunoassay of the “‘In-DTPA-a.HCG 
conjugate (C--O) and of the a.HCG used for its 
preparation (A--A). 
Table 1 
M~imum specific activities achieved on Iabelling a 
series of DTPA-IgG conjugates 
Molar ratio DTPA-IgG used Spec. act. 
in preparation of conjugate (MBq/mgl 
5 107 
10 172 
15 269 
20 270 
1Oa 68 
“No ~-hydroxysuccinimide was used during the 
preparation of this conjugate 
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Fig.2. Gel filtration of the ‘“In-DTPA-a.HCG 
conjugate and of the a.HCG used for its preparation. 
(A) Absorbance trace obtained for the a.HCG. (B) Trace 
for the conjugate. (C) Radioactivity of the same 
conjugate fractions. 
and also illustrates the firm binding of the “‘In to 
the conjugate. Weakly bound ‘“In would be 
removed as a citrate complex during the post- 
iabelling gel filtrations. 
We believe that this procedure affords a reliable 
way of Iabelling antibodies with “‘In and that 
because of its ease, efficiency and mild reaction 
conditions, it offers an advantage over existing 
methods. 
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